Thalamic gliomas: A clinicopathologic analysis of 20 cases with reference to patient age

S. Nishio, T. Morioka, Satoshi Suzuki, I. Takeshita, M. Fukui

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Twenty patients (M 11, F 9; ranging from 1-77 years old) with histologically proven glial tumours in the thalamic region, treated from 1979 until 1994 at Kyushu University Hospital were retrospectively reviewed and analysed in order to elucidate their clinical and neuropathological characteristics. The initial common clinical manifestations were those of increased intracranial pressure or motor weakness. The histological diagnosis of the tumour was pilocytic astrocytoma in 2 patients, fibrillary astrocytoma in 7, anaplastic astrocytoma in 7, and glioblastoma multiforme in 4. The initial treatment was surgery alone in 4 patients, surgery followed by radiation therapy in 5, surgery followed by radiation therapy and chemotherapy in 9, and conventional radiation therapy alone in 2 patients. The 3-year overall actuarial survival rate for all patients was 20% but was related to both the histological type and the age of the patients: As a result, the rate was 44% for patients with low-grade astrocytoma compared to 0% for those with high-grade astrocytoma. While 5 out of 11 patients under the age of 25 years at their initial presentation have survived for from 2-16 years after the diagnosis, all patients presenting after the age of 25 years died within 3 years after treatment. Thalamic glial tumours are not a homogeneous group of tumours in terms of clinical behaviour and histopathological features, and the poor overall results, especially in adult tumours, thus emphasise the need for continued research in the treatment of these tumours.

Original languageEnglish
Pages (from-to)336-342
Number of pages7
JournalActa Neurochirurgica
Volume139
Issue number4
DOIs
Publication statusPublished - Jan 1 1997

Fingerprint

Glioma
Astrocytoma
Neoplasms
Radiotherapy
Neuroglia
Intracranial Pressure
Glioblastoma
Therapeutics
Survival Rate
Drug Therapy
Research

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Thalamic gliomas : A clinicopathologic analysis of 20 cases with reference to patient age. / Nishio, S.; Morioka, T.; Suzuki, Satoshi; Takeshita, I.; Fukui, M.

In: Acta Neurochirurgica, Vol. 139, No. 4, 01.01.1997, p. 336-342.

Research output: Contribution to journalArticle

Nishio, S. ; Morioka, T. ; Suzuki, Satoshi ; Takeshita, I. ; Fukui, M. / Thalamic gliomas : A clinicopathologic analysis of 20 cases with reference to patient age. In: Acta Neurochirurgica. 1997 ; Vol. 139, No. 4. pp. 336-342.
@article{f53389b40fc4466c99c1bbfdf21de676,
title = "Thalamic gliomas: A clinicopathologic analysis of 20 cases with reference to patient age",
abstract = "Twenty patients (M 11, F 9; ranging from 1-77 years old) with histologically proven glial tumours in the thalamic region, treated from 1979 until 1994 at Kyushu University Hospital were retrospectively reviewed and analysed in order to elucidate their clinical and neuropathological characteristics. The initial common clinical manifestations were those of increased intracranial pressure or motor weakness. The histological diagnosis of the tumour was pilocytic astrocytoma in 2 patients, fibrillary astrocytoma in 7, anaplastic astrocytoma in 7, and glioblastoma multiforme in 4. The initial treatment was surgery alone in 4 patients, surgery followed by radiation therapy in 5, surgery followed by radiation therapy and chemotherapy in 9, and conventional radiation therapy alone in 2 patients. The 3-year overall actuarial survival rate for all patients was 20{\%} but was related to both the histological type and the age of the patients: As a result, the rate was 44{\%} for patients with low-grade astrocytoma compared to 0{\%} for those with high-grade astrocytoma. While 5 out of 11 patients under the age of 25 years at their initial presentation have survived for from 2-16 years after the diagnosis, all patients presenting after the age of 25 years died within 3 years after treatment. Thalamic glial tumours are not a homogeneous group of tumours in terms of clinical behaviour and histopathological features, and the poor overall results, especially in adult tumours, thus emphasise the need for continued research in the treatment of these tumours.",
author = "S. Nishio and T. Morioka and Satoshi Suzuki and I. Takeshita and M. Fukui",
year = "1997",
month = "1",
day = "1",
doi = "10.1007/BF01808830",
language = "English",
volume = "139",
pages = "336--342",
journal = "Acta Neurochirurgica",
issn = "0001-6268",
publisher = "Springer Wien",
number = "4",

}

TY - JOUR

T1 - Thalamic gliomas

T2 - A clinicopathologic analysis of 20 cases with reference to patient age

AU - Nishio, S.

AU - Morioka, T.

AU - Suzuki, Satoshi

AU - Takeshita, I.

AU - Fukui, M.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Twenty patients (M 11, F 9; ranging from 1-77 years old) with histologically proven glial tumours in the thalamic region, treated from 1979 until 1994 at Kyushu University Hospital were retrospectively reviewed and analysed in order to elucidate their clinical and neuropathological characteristics. The initial common clinical manifestations were those of increased intracranial pressure or motor weakness. The histological diagnosis of the tumour was pilocytic astrocytoma in 2 patients, fibrillary astrocytoma in 7, anaplastic astrocytoma in 7, and glioblastoma multiforme in 4. The initial treatment was surgery alone in 4 patients, surgery followed by radiation therapy in 5, surgery followed by radiation therapy and chemotherapy in 9, and conventional radiation therapy alone in 2 patients. The 3-year overall actuarial survival rate for all patients was 20% but was related to both the histological type and the age of the patients: As a result, the rate was 44% for patients with low-grade astrocytoma compared to 0% for those with high-grade astrocytoma. While 5 out of 11 patients under the age of 25 years at their initial presentation have survived for from 2-16 years after the diagnosis, all patients presenting after the age of 25 years died within 3 years after treatment. Thalamic glial tumours are not a homogeneous group of tumours in terms of clinical behaviour and histopathological features, and the poor overall results, especially in adult tumours, thus emphasise the need for continued research in the treatment of these tumours.

AB - Twenty patients (M 11, F 9; ranging from 1-77 years old) with histologically proven glial tumours in the thalamic region, treated from 1979 until 1994 at Kyushu University Hospital were retrospectively reviewed and analysed in order to elucidate their clinical and neuropathological characteristics. The initial common clinical manifestations were those of increased intracranial pressure or motor weakness. The histological diagnosis of the tumour was pilocytic astrocytoma in 2 patients, fibrillary astrocytoma in 7, anaplastic astrocytoma in 7, and glioblastoma multiforme in 4. The initial treatment was surgery alone in 4 patients, surgery followed by radiation therapy in 5, surgery followed by radiation therapy and chemotherapy in 9, and conventional radiation therapy alone in 2 patients. The 3-year overall actuarial survival rate for all patients was 20% but was related to both the histological type and the age of the patients: As a result, the rate was 44% for patients with low-grade astrocytoma compared to 0% for those with high-grade astrocytoma. While 5 out of 11 patients under the age of 25 years at their initial presentation have survived for from 2-16 years after the diagnosis, all patients presenting after the age of 25 years died within 3 years after treatment. Thalamic glial tumours are not a homogeneous group of tumours in terms of clinical behaviour and histopathological features, and the poor overall results, especially in adult tumours, thus emphasise the need for continued research in the treatment of these tumours.

UR - http://www.scopus.com/inward/record.url?scp=0030944916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030944916&partnerID=8YFLogxK

U2 - 10.1007/BF01808830

DO - 10.1007/BF01808830

M3 - Article

C2 - 9202774

AN - SCOPUS:0030944916

VL - 139

SP - 336

EP - 342

JO - Acta Neurochirurgica

JF - Acta Neurochirurgica

SN - 0001-6268

IS - 4

ER -